So far CRMO and related comorbidities have been treated successfully by the administration of IL-1-Receptor antagonists like anakinra, emphasizing the importance of IL-1β and neutrophil activation [21–26]. Here, IL1B is linked to chronic recurrent multifocal osteomyelitis.